Pharmanovia, a global pharmaceutical company that commercializes new drugs and revitalizes, extends, and expands the lifecycle of existing drugs, is expanding its neurology portfolio through the acquisition of 11 central nervous system (CNS) brands from global healthcare company Sanofi.
The brand spans four therapeutic areas with unmet needs related to central nervous system disorders: tranquilizers, anxiolytics, anticonvulsants, and antipsychotics.
Clobazam is a class of drugs called benzodiazepines that may be used to treat anxiety with or without insomnia and certain mental conditions in certain patients. Acquired brands include Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbanan, Noiafren and Castilium. Frisium may also be used as an adjunctive therapy for epilepsy.
Phenobarbital is used as an anticonvulsant to treat all types of epilepsy except absence seizures.
Cyamemazine is used to treat certain mental conditions and anxiety in patients who have not improved with other treatments and in combination with other antidepressants to treat some forms of depression. used for treatment.
Prochlorperazine is used to treat dizziness, nausea, and vomiting caused by a variety of causes. It may also be used to treat conditions such as schizophrenia and acute mania, and as an adjunct to control anxiety in the short term.
Dr. James Burt, CEO of Pharmanovia, commented: “Sanofi’s decision to sell its well-established central nervous system portfolio, with leading brands such as Frisium and Gardenal, to Pharmanovia is a result of Sanofi’s neurology expertise, lifecycle management capabilities, and reliable sales partner. Not only do we ensure that these important medicines continue to be supplied to the millions of patients who need them, but we also ensure that our lifecycle management services provide the best possible care for patients. We are excited to leverage this knowledge and our global platform to ensure we continue to evolve to meet your needs.”
“Through this acquisition, we are not only deepening our roots in the region. There are still significant unmet needs in mental health and epilepsy.”
